The Advances in Genome Biology and Know-how (AGBT) assembly celebrated its 25th anniversary in sunny Marco Island, Florida, with the customary combine of massive identify audio system addressing researchers and executives within the next-generation sequencing (NGS), single cell, and spatial fields (together with Ewan Birney, PhD, deputy director of EMBL) and past (former U.S. President Invoice Clinton). Many of the consideration centered on product bulletins by key corporations within the subject and those who want to be, lots of them are summarized beneath.
This A-Checklist presents two lists of sequencing instrument suppliers. One listing consists of eight corporations that present NGS devices. The opposite consists of three corporations that present Sanger sequencing-based devices. (One firm, Thermo Fisher Scientific, seems in each lists). Additionally listed individually are three corporations whose sequencing choices consist primarily of workflow options—Agilent Applied sciences, QIAGEN, and Revvity. As with final 12 months’s A-Checklist, every firm is listed by identify adopted by a brief description of their current exercise.
Not included this 12 months is Singular Genomics. Over the previous 12 months, Singular has pivoted to spatial sequencing by means of its G4X® Spatial Sequencer, asserting an early entry program in February with preliminary shipments deliberate for June. On February 21, a Deerfield Administration affiliate closed on its acquisition of Singular for $20 a share—a $50.2 million deal primarily based on Singular’s 2.51 million excellent shares, in keeping with FactSet knowledge. The deal took Singular personal and adjusted its management, with a reconstituted board and a change of CEOs.
Suppliers of NGS Instrumentation |
Aspect BiosciencesAll through 2025, Aspect Biosciences plans to roll out a sequence of upgrades or “Innovation Roadmap” for the top-tier AVITI24™ sequencing system it launched final 12 months. Amongst enhancements set for the second half of this 12 months are direct in-sample sequencing for a variety of latest use circumstances, together with utterly library-prep free, unbiased entire transcriptome, and focused RNA sequencing. Privately-held Aspect disclosed an estimated 2024 income of roughly $60 million in January on the 43rd Annual J.P. Morgan Healthcare Convention. |
IlluminaIllumina has introduced a spatial know-how program designed to assist researchers study the spatial proximity of tens of millions of cells per experiment, set for business launch in 2026. The longtime NGS chief additionally introduced a single cell collaboration with Broad Medical Labs, and a collaboration with Nvidia to use genomics and AI to research and interpret multiomic knowledge in drug discovery, medical analysis, and human well being. In March, China banned the import of Illumina sequencers, in obvious retaliation for President Donald Trump levying tariffs on the nation. Illumina completed 2024 with a $1.223 billion internet loss on income of $4.372 billion. |
MGI TechMGI Tech has unveiled by means of U.S. subsidiary Full Genomics two new upgraded variations of its DNBSEQ next-gen sequencing system. One is DNBSEQ-T1+, a mid-throughput instrument designed to finish a paired finish 150 sequencing workflow in 24 hours with Q40 accuracy, a throughput vary of 25–1,200 Gb, and a most capability exceeding 1 Tb every day. The opposite new sequencer, DNBSEQ-E25 Flash, is an upgraded model of the present moveable DNBSEQ-E25 sequencer that leverages AI-optimized protein engineering for enhanced sign depth and precision, constructing on self-luminescence know-how and a CMOS-based stream cell. |
Oxford Nanopore Applied sciencesDeclaring 2025 “the 12 months of the proteome,” Oxford Nanopore Applied sciences co-founder and CEO Gordon Sanghera has highlighted his firm’s dedication over the following 5 years to mix proteomics with multiomics in its menu of sequencing choices. In February, Oxford Nanopore introduced a veterinary diagnostics collaboration with PathoSense designed to consolidate a number of conventional infectious illness checks into one inexpensive and accessible resolution powered by Oxford Nanopore’s sequencing know-how, together with the MinION machine’s scalable capabilities. ONT completed final 12 months with a lack of £146.2 million ($189.7 million) on income of £183.1 million ($237.6 million). |
RocheRoche generated buzz at AGBT after introducing its SBX (Sequencing by Growth) know-how. SBX makes use of biochemical conversion to encode DNA right into a surrogate molecule known as an Xpandomer (50x longer than goal DNA) and encodes the DNA sequence data in giant, excessive signal-to-noise reporters. Based on Roche, that permits extremely correct single-molecule nanopore sequencing utilizing a Complementary Steel Oxide Semiconductor (CMOS)-based sensor module. Roche Sequencing Options is inside Roche’s Diagnostics Division, which final 12 months generated CHF 14.324 billion ($15.954 billion) in income. |
Thermo Fisher ScientificThermo Fisher Scientific markets NGS know-how below the Ion Torrent identify. Final summer season, Thermo Fisher started partnering with the NIH’s Nationwide Most cancers Institute on the myeloMATCH (Molecular Evaluation for Remedy Alternative) precision medication umbrella trial. Utilizing Thermo Fisher’s NGS know-how to check sufferers’ bone marrow and blood for genetic biomarkers, medical websites intention to match sufferers extra rapidly with essentially the most appropriate medical trial assessing a therapy concentrating on particular mutations. Sequencing is inside Thermo Fisher’s Life Sciences Options section, which in 2024 generated $9.631 billion (22.5%) of the corporate’s $42.879 billion in income. |
Ultima GenomicsUltima Genomics, on February 24, commercially launched its UG 100 Solaris™ sequencing system, an improve of the UG 100™ sequencing platform launched final 12 months that options new chemistry, software program, and simplified workflows designed to considerably enhance output and decrease value. Solaris provides a >50% enhance in output to 10 to 12 billion reads per wafer, and a 20% value discount to 24 cents per million reads—a value Ultima says permits the $80 genome. Privately held Ultima emerged from stealth in 2022, elevating roughly $600 million. |
Suppliers of Sanger Sequencing Instrumentation |
Hitachi Excessive-TechHitachi Excessive-Tech joined Nabsys 2.0 on February 21 to disclose 15 awardees of their OhmX Fast Software to Market Penetration Person Partnership (RAMP UP) Grant Program. Winners are pursuing quite a few functions of the OhmX Analyzer for structural variant evaluation, together with orthogonal affirmation of long-read sequencing calls. Hitachi markets the Compact CE Sequencer DS3000, designed to facilitate sequencing evaluation and fragment evaluation. For the fiscal 12 months ending March 31, 2024, Hitachi Excessive-Tech reported roughly ¥670.449 billion ($4.463 billion) in income. |
PromegaPrivately-held Promega markets the Spectrum Compact Capillary Electrophoresis (CE) system, a benchtop instrument supporting Sanger sequencing functions for verification of NGS base calls. Additionally it is designed to substantiate profitable genome edits in reworked cultures and to display screen secondary clones for profitable enhancing occasions utilizing CRISPR-Cas9 strategies. Spectrum Compact CE additionally helps next-generation 8-color STR kits and can be used for DNA fragment evaluation for forensic labs. |
Thermo Fisher ScientificThermo Fisher Scientific markets genetic analyzers and workflow instruments for Sanger sequencing below the Utilized Biosystems model. Final September, Thermo Fisher launched the Utilized Biosystems InnoviGene™ Suite, an intuitive, browser-based software program platform for automating and optimizing CE knowledge evaluation, enabling 21 CFR Half 11 compliance. Utilized Biosystems’ SeqStudio Collection programs, such because the SeqStudio Flex Collection Genetic Analyzer, are designed to research nucleic acids utilizing CE with Sanger sequencing or fragment evaluation and allow functions starting from easy focused sequencing to identification of SARS variants of concern. |
Suppliers of Workflow Options |
Agilent Applied sciencesPresident and CEO Padraig McDonnell isn’t quantifying Agilent’s genomics enterprise, which his predecessor Mike McMullen pegged at $500 million in FY 2023. In FY 2024, McDonnell stated, genomics “posted low single-digit progress” forward of expectations. Simon Could, senior VP and President of Agilent’s Life Sciences and Diagnostics Markets Group, cited the Magnis NGS Prep System (“continues to see unbelievable traction”) and Avida DNA Reagent Equipment (“very inspired”). |
QIAGENGenomics England chosen the QIAGEN Medical Information Base (and Revvity’s chemagic™ 360 automated nucleic extraction instrument) in January to help the Technology Examine, which goals to sequence the genomes of 100,000 newborns to display screen for >200 chosen genetic situations. QIAGEN stated progress in common consumables used on third-party NGS programs supported the 1% year-over-year enhance in This autumn 2024 gross sales for its Genomics/NGS enterprise, to $66 million. Full-year genomics/NGS gross sales slid 2% to $234 million. |
RevvityRvvity agreed in January to mix its automated NGS workflow with Aspect Bioscience’s AVITI system to co-develop a complete in vitro diagnostic (IVD) workflow resolution for neonatal sequencing. As a part of its new child sequencing analysis workflow, Revvity markets and commercializes to its NGS clients Bionano Genomics’ VIA™ software program. Revvity, previously Perkin Elmer’s diagnostics and life sciences enterprise, completed 2024 with a $12.686 million internet loss on income that inched up 0.1% to $2.755 billion. |
